scispace - formally typeset
Journal ArticleDOI

Comparison of 18 F-FDG PET/CT methods of analysis for predicting response to neoadjuvant chemoradiation therapy in patients with locally advanced low rectal cancer

Reads0
Chats0
TLDR
Qualitative and semiquantitative evaluations for 18F-FDG PET/CT evaluations for LARC are the optimal approach; a valid parameter for response prediction has still to be established.
Abstract
The aim of this study was to prospectively investigate the predictive value of 18F-FDG PET/CT semiquantitative parameters for locally advanced low rectal cancer (LARC) treated by neoadjuvant chemoradiation therapy (nCRT). 68 patients with LARC had 18F-FDG PET/CT scans twice (baseline and 5–6 weeks post-nCRT). All patients underwent surgery with preservation of the sphincter 8 weeks later. 18F-FDG PET/CT analysis was performed by visual response assessment (VRA) and semiquantitative parameters: SUVmaxbaseline, SUVmeanbaseline, MTVbaseline, TLGbaseline, SUVmaxpost-nCRT, SUVmeanpost-nCRT, MTVpost-nCRT, TLGpost-nCRT; ΔSUVmax and mean and Response indexes (RImax% and RImean%). Assessment of nCRT tumor response was performed according to the Mandard’s Tumor Regression Grade (TRG) and (y)pTNM staging on the surgical specimens. Concordances of VRA with TRG, and with (y)pTNM criteria were evaluated by Cohen’s K. Results were compared by t student test for unpaired groups. ROC curve analysis was performed. VRA analysis of post-nCRT 18F-FDG PET/CT scan for the (y)pTNM outcome showed sensitivity, specificity, accuracy, PPV, and NPV of 87.5%, 66.7%, 83.8%, 92.5%, and 53.3%, respectively. Concordances of VRA with TRG and with (y)pTNM were moderate. For the outcome variable TRG, the statistical difference between responders and non-responders was significant for SUVmaxpost-nCRT and RImean%; for the outcome variable (y)pTNM, there was a significant difference for MTVbaseline, SUVmaxpost-nCRT, SUVmeanpost-nCRT, MTVpost-nCRT, RImax%, and RImean%. ROC analysis showed better AUCs: for the outcome variable TRG for SUVmaxpost-nCRT, SUVmeanpost-nCRT, and RImean%; for the outcome variable (y)pTNM for MTVbaseline, SUVmaxpost-nCRT, SUVmeanpost-nCRT, MTVpost-nCRT, RImax%, and RImean%. No significant differences among parameters were found. Qualitative and semiquantitative evaluations for 18F-FDG PET/CT are the optimal approach; a valid parameter for response prediction has still to be established.

read more

Citations
More filters
Journal ArticleDOI

Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials.

TL;DR: The neoadjuvant rectal (NAR) score offers an opportunity to incorporate a novel surrogate endpoint into early phase rectal cancer clinical trials, based upon variables routinely collected and available to clinical investigators during the conduct of prospective studies.
Journal ArticleDOI

18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography.

TL;DR: The 18F-FDG PET/CT is a useful tool for the evaluation of gastric carcinoma to detect primary lesion, lymphnode, and distant metastases using 1 single image whole-body technique.
Journal ArticleDOI

Magnetic Resonance Imaging evaluation in neoadjuvant therapy of Locally Advanced Rectal Cancer: a systematic review

TL;DR: Morphological MRI is the modality of choice for rectal cancer staging permitting a correct assessment of the disease extent, of the lymph node involvement, ofThe mesorectal fascia and of the sphincter complex for surgical planning.
Journal ArticleDOI

Volumetric parameters changes of sequential 18F-FDG PET/CT for early prediction of recurrence and death in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.

TL;DR: The data suggest that MTV on initial pretreatment 18F-FDG PET/CT and &Dgr;TLG after preoperative concurrent chemoradiotherapy in LARC patients could provide prognostic information and were the potent predictors for RFS and OS.
Journal ArticleDOI

The use of PET/MRI for imaging rectal cancer

TL;DR: Overall PET/MRI can improve the staging of rectal cancer, although this potential has yet to be fulfilled.
References
More filters
Journal ArticleDOI

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

TL;DR: Qualitative and quantitative approaches to 18F-FDG PET response assessment have been applied and require a consistent PET methodology to allow quantitative assessments and the proposed PERCIST 1.0 criteria should serve as a starting point for use in clinical trials and in structured quantitative clinical reporting.
Journal ArticleDOI

Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations.

TL;DR: A pilot study was undertaken to determine if pathologic assessment of tumor regression correlated with disease free survival in patients with esophageal carcinoma.
Journal ArticleDOI

Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.

TL;DR: Stage 0 rectal cancer disease is associated with excellent long-term results irrespective of treatment strategy and Surgical resection may not lead to improved outcome in this situation and may be associated with high rates of temporary or definitive stoma construction and unnecessary morbidity and mortality rates.
Journal ArticleDOI

Prognostic Significance of Tumor Regression After Preoperative Chemoradiotherapy for Rectal Cancer

TL;DR: In this exploratory analysis, complete ( TRG 4) and intermediate pathologic response (TRG 2 + 3) suggested improved DFS after preoperative CRT, and TRG assessment should be implemented in pathologic evaluation and prospectively validated in further studies.
Related Papers (5)